ESR1 and breast cancer: The combination of the miR-200c expression levels with other clinicopathological parameters, such as lymph node infiltration, tumor grade, and estrogen receptor status, predicted late relapse in this BC cohort, suggesting their intriguing efficacy as biomarkers for BC recurrence [41].